Have a personal or library account? Click to login
The significance of HERC5, IFIH1, SAMD4, SEMA3A and MCTP1 genes expression in resistance to cytotoxic drugs in ovarian cancer cell lines Cover

The significance of HERC5, IFIH1, SAMD4, SEMA3A and MCTP1 genes expression in resistance to cytotoxic drugs in ovarian cancer cell lines

Medical Journal of Cell Biology
Volume 9 (2021): Issue 3 (September 2021)
By: Marta Nowacka,  Barbara Ginter-Matuszewska,  Monika Świerczewska,  Michał Nowicki,  Maciej Zabel,  Karolina Sterzyńska and  Radosław Januchowski  
Open Access
|Sep 2021

Figures & Tables

FIGURE 1

Expression analysis (Q-PCR) of the HERC5 (A), IFIH1 (B), and SAMD4 (C) transcripts in different ovarian cancer cell lines. The figure presents the relative gene expression in cell lines (grey bars) with respect to the W1 cell line (white bar), which was assigned a value of 1. The values were considered significant at *p<0.05, **p<0. 0 and ***p<0.001
Expression analysis (Q-PCR) of the HERC5 (A), IFIH1 (B), and SAMD4 (C) transcripts in different ovarian cancer cell lines. The figure presents the relative gene expression in cell lines (grey bars) with respect to the W1 cell line (white bar), which was assigned a value of 1. The values were considered significant at *p<0.05, **p<0. 0 and ***p<0.001

FIGURE 2

Expression analysis (Q-PCR) of the SEMA3A (A) and MCTP1 (B) transcripts in different ovarian cancer cell lines. The figure presents the relative gene expression in cell lines (grey bars) with respect to the W1 cell line (white bar), which was assigned a value of 1. The values were considered significant at *p<0.05, **p<0.01 and ***p<0.001
Expression analysis (Q-PCR) of the SEMA3A (A) and MCTP1 (B) transcripts in different ovarian cancer cell lines. The figure presents the relative gene expression in cell lines (grey bars) with respect to the W1 cell line (white bar), which was assigned a value of 1. The values were considered significant at *p<0.05, **p<0.01 and ***p<0.001

Summary of cell lines resistance to cisplatin, paclitaxel, doxorubicin and topotecan treatment

Cell lineIC50 (ng/ml)
cisplatinpaclitaxeldoxorubicintopotecan
W1151 (96–216)13,37 (3,18–3,62)113,6 (9,1–18,0)12,03 (1,94–2,11)1
A2780439 (283–565)2,9 ↑*3,43 (1,91–4,73)1,02 ↑19,79 (12,52–24,44)1,46 ↑3,13 (1,48–4,71) 1,54 ↑
SKOV-3890 (595–1222)5,8 ↑**0,784 (0,73–0,84)4,30 ↑**17,76 (13,7–22,84)1,31 ↑51,9 (40,34–60,71)25,6 ↑***
OVCAR-32613 (2125–2884)17,3 ↑***458 (372–594)136 ↑***354 (203–571)26 ↑**398 (283–505) 196↑***
PEA12737 (2031–3763)18,1 ↑**5,66 (3,25–9,07)1,68 ↑81 (72–90)5,96 ↑**29 (19,2–46,9)14,3 ↑**
PEA22469 (2426–2557)16,4 ↑***6,88 (4,31–8,38)2,04 ↑*173 (148–195)12,7 ↑**132 (79–188)65 ↑**
PEO232171 (1839–2438)14,4 ↑***1404 (1000–1600)417 ↑***275 (198–375)20,2 ↑***498 (300–750)245 ↑**

Characterization of cell lines used in this study

Cell lineOriginChemotherapyTreatment outcome
W1tumor tissue, ovarian serous adenocarcinomaNoN/A
A2780tumour tissue, ovarian endometrioid adenocarcinomaNoN/A
SKOV-3ascites, ovarian serous adenocarcinomaThioTEPAineffective
OVCAR-3ascites, ovarian serous adenocarcinoma, high gradecyclophosphamide, DOX, CISineffective
PEA1pleural effusion, serous adenocarcinoma, high gradeNoN/A
PEA2ascites, serous adenocarcinoma, high gradeCIS, Prednimustineineffective
PEA O23ascites, serous adenocarcinoma, low gradeCIS, chlorambucilineffective

Oligonucleotide sequences used for Q-PCR analysis

TranscriptSequence (5′-3′ direction)ENST numberProduct size
MCTP1FAGAACCTCAACCCTGTGTGG00000312216123 bp
RAGGCTGAGCCCATAAAGTCA
IFIH1FGGGGCATGGAGAATAACTCA00000263642132 bp
RTGCCCATGTTGCTGTTATGT
SAMD4FCCAAAGGTGCAAGACACAAA00000251091146 bp
RCGGAGTCAGGATCATCTGGT
HERC5FCTTCCTGCATGTGGTTTCCT00000264350128 bp
RAAACAGTGCCAGTGGGAAAG
SEMA3AFTGTTGGAGCAAAGGATCACA00000265362109 bp
RAGCCCACTTGCATTCATCTC
GAPDHFGAAGGTGAAGGTCGGAGTCA00000229239199 bp
RGACAAGCTTCCCGTTCTCAG
β-actinFTCTGGCACCACACCTTCTAC00000331789169 bp
RGATAGCACAGCCTGGATAGC
HPRT1FCTGAGGATTTGGAAAGGGTG00000298556156 bp
RAATCCAGCAGGTCAGCAAAG
B2MFCGCTACTCTCTCTTTCTGGC00000558401133 bp
RATGTCGGATGGATGAAACCC
DOI: https://doi.org/10.2478/acb-2021-0019 | Journal eISSN: 2544-3577
Journal RSS Feed
Language: English
Page range: 138 - 147
Submitted on: Jul 14, 2021
|
Accepted on: Aug 29, 2021
|
Published on: Sep 27, 2021
Published by: Foundation for Cell Biology and Molecular Biology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
ovarian cancer,
cytotoxic drug resistance,
new genes
Related subjects:
Life sciences,
Molecular biology,
Biochemistry

© 2021 Marta Nowacka, Barbara Ginter-Matuszewska, Monika Świerczewska, Michał Nowicki, Maciej Zabel, Karolina Sterzyńska, Radosław Januchowski, published by Foundation for Cell Biology and Molecular Biology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 9 (2021): Issue 3 (September 2021)